Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 89, Issue 1, Pages 129-139Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2013.08.004
Keywords
IL-6; Angiogenesis; VEGF; STAT3; HIF-1 alpha; Bevacizumab; Sunitinib; Siltuximab
Categories
Funding
- Cancer Council Queensland
- Mater Foundation, Brisbane, Australia
Ask authors/readers for more resources
During the past decade, incorporating anti-angiogenic agents into the therapeutic management of a myriad of malignancies has in certain cases made a significant impact on survival. However, the development of resistance to these drugs is inevitable and swift disease progression on their cessation often ensues. Hence, there is a drive to devise strategies that aim to enhance response to anti-angiogenic therapies by combining them with other targeted agents that facilitate evasion from resistance. The pleiotropic cytokine, interleukin-6 (IL-6), exerts proangiogenic effects in the tumour microenvironment of several solid malignancies and there is emerging evidence that reveals significant relationships between IL-6 signalling and treatment failure with antibodies directed against vascular endothelial growth factor (VEGF). This review summarises the role of IL-6 in pivotal angiogenic processes and preclinical/clinical research to support the future introduction of anti-IL-6 therapies to be utilised either in combination with other anti-angiogenic drugs or as a salvage therapy for patients with diseases that become refractory to these approaches. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available